PHARMACOKINETICS OF INTRAPLEURAL VERSUS INTRAVENOUS ETOPOSIDE (VP-16) AND TENIPOSIDE (VM-26) IN PATIENTS WITH MALIGNANT PLEURAL EFFUSION

被引：0
|
作者：
MONTALDO, PG
FIGOLI, F
ZANETTE, ML
SORIO, R
ZUCCHETTI, M
TIRELLI, U
DINCALCI, M
机构：
[1] MARIO NEGRI INST PHARMACOL RES,VIA ERITREA 62,I-20157 MILAN,ITALY
[2] CTR RIFERIMENTO ONCOL,AVIANO,ITALY
来源：
ONCOLOGY | 1990年 / 47卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：55 / 61
页数：7
相关论文
共 50 条
  • [21] GENETIC-DAMAGE INDUCED BY DERIVATIVES OF PODOPHYLLOTOXIN, VM-26 AND VP-16 .1.
    LARRIPA, IB
    CARBALLO, MA
    DEPARGAMENT, MDM
    FLOCK, G
    DEVINUESA, MLL
    ACTA PHYSIOLOGICA ET PHARMACOLOGICA LATINOAMERICANA, 1987, 37 (01): : 110 - 111
  • [22] INHIBITION OF 1-BETA-D-ARABINOFURANOSYLCYTOSINE (ARAC) TRANSPORT AND NET ACCUMULATION BY TENIPOSIDE (VM-26) AND ETOPOSIDE (VP-16) IN EHRLICH ASCITES-CELLS AND HUMAN-LEUKEMIC BLASTS
    WHITE, JC
    HINES, LH
    RATHMELL, JP
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1985, 26 (MAR): : 323 - 323
  • [23] CLINICAL-PHARMACOLOGY OF VM-26 (NSC 122819) AND VP-16 (NSC 141540) IN CHILDREN WITH CANCER
    EVANS, WE
    SINKULE, JA
    HORVATH, A
    CROM, WR
    DOW, LW
    RIVERA, G
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1981, 22 (MAR): : 174 - 174
  • [24] TENIPOSIDE (VM-26)-INDUCED AND ETOPOSIDE (VP-16-213)-INDUCED AUGMENTATION OF METHOTREXATE TRANSPORT AND POLYGLUTAMYLATION IN EHRLICH ASCITES TUMOR-CELLS INVITRO
    YALOWICH, JC
    FRY, DW
    GOLDMAN, ID
    CANCER RESEARCH, 1982, 42 (09) : 3648 - 3653
  • [25] INHIBITION OF TOPOISOMERASE-II BY VP-16-213 (ETOPOSIDE) VM-26 (TENIPOSIDE), AND STRUCTURAL CONGENERS AS AN EXPLANATION FOR INVIVO DNA BREAKAGE AND CYTO-TOXICITY
    LONG, BH
    MINOCHA, A
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1983, 24 (MAR): : 321 - 321
  • [26] ETOPOSIDE (VP16-213) AND TENIPOSIDE (VM26) COMPARATIVE INVITRO ACTIVITIES IN HUMAN-TUMORS
    ISSELL, BF
    TIHON, C
    CURRY, ME
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1982, 7 (2-3) : 113 - 115
  • [27] COMBINATION CHEMOTHERAPY FOR PATIENTS WITH RELAPSED MALIGNANT-LYMPHOMA USING METHYL-GAG AND TENIPOSIDE (VM-26)
    WARRELL, RP
    STRAUS, DJ
    YOUNG, CW
    CANCER TREATMENT REPORTS, 1982, 66 (05): : 1121 - 1125
  • [28] Carboplatin and cisplatin pharmacokinetics after intrapleural combination treatment in patients with malignant pleural effusion
    Lerza, R
    Vannozzi, MO
    Tolino, G
    Viale, M
    Bottino, GB
    Bogliolo, G
    Cerruti, A
    Castello, G
    Mencoboni, M
    Reggiardo, G
    Pannacciulli, I
    Esposito, M
    ANNALS OF ONCOLOGY, 1997, 8 (04) : 385 - 391
  • [29] ETOPOSIDE (VP16) AND TENIPOSIDE (VM26) - NOVEL ANTICANCER DRUGS, STRONGLY MUTAGENIC IN MAMMALIAN BUT NOT PROKARYOTIC TEST SYSTEMS
    GUPTA, RS
    BROMKE, A
    BRYANT, DW
    GUPTA, R
    SINGH, B
    MCCALLA, DR
    MUTAGENESIS, 1987, 2 (03) : 179 - 186
  • [30] CYTOTOXICITY AND EXTENT OF PROTEIN ASSOCIATED DNA STRAND BREAKS BY ETOPOSIDE (VP-16-213) AND TENIPOSIDE (VM-26) AND THEIR QUINONE METABOLITES IN A HUMAN-BREAST CANCER CELL-LINE
    KENNEDY, KA
    NEMEC, J
    BATIST, G
    SINHA, BK
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1986, 27 : 278 - 278
12345